EUVIMEDEUVIMED entdecken
Crossref

Correlation between MASCC score and the evolution of febrile neutropenia in patients with solid tumors: a retrospective study

Charles-Eric Rivest, Fatim Ezzahra Ben Abderrazik, Marc-Antoine Côté-Marcoux, Mandy Malick, Catherine Allard, Robert Hanel, Michel Pavic

Supportive Care in Cancer · 2026-02 · 34 (2)

DOI: 10.1007/s00520-026-10375-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 29.01.2026. Verfasst von Charles-Eric Rivest und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Sherbrooke (CHUS), 3001 12E Avenue Nord, Sherbrooke, QC, J1H 5H3, Canada. charles-eric.rivest@usherbrooke.ca. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Febrile Neutropenia, Chemotherapy-Induced Febrile Neutropenia. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The MASCC (Multinational Association for Supportive Care in Cancer) score is widely used to identify low-risk febrile neutropenia (FN) patients eligible for outpatient management. However, its performance specifically in patients with solid tumors remains insufficiently validated. METHODS: We conducted a retrospective cohort study at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between 2011 and 2022. Adult patients admitted for FN secondary to chemotherapy for solid tumors were included. Patients were classified as high-risk (MASCC < 21) or low-risk (MASCC ≥ 21). The primary outcome was the score's ability to predict an uncomplicated clinical course with a specificity of 95%. Secondary outcomes included ICU admission, mortality, duration of hospitalization, intravenous antibiotics, neutropenia, and potential days saved with outpatient treatment. RESULTS: Among 329 oncologic patients, 227 (69%) were classified as low risk. The MASCC score showed a sensitivity of 83.5% (95% CI 77.8-88.2%) and a specificity of 57.3% (95% CI 47.8-66.4%) for predicting the absence of complications. ICU admission rates were significantly lower among low-risk patients (0.4% vs. 32.7%, p < 0.001), as were mortality rates (0.9% vs. 16.8%, p < 0.001). Median hospitalization duration was 4 days [IQR (interquartile range) 3-6] for low-risk patients compared to 6 days [IQR 4-10] for high-risk patients (p < 0.001). Applying outpatient eligibility criteria could have prevented 486 hospitalization days across 161 patients, with 80.7% experiencing no complications. CONCLUSION: The MASCC score does not accurately identify solid tumor FN patients who would evolve without complications, given its moderate specificity. However, it remains associated with a substantial reduction in hospitalization burden among low-risk patients. Clinical judgment remains essential in outpatient management decisions. Integrating additional clinical parameters may further improve risk stratification in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsFebrile NeutropeniaChemotherapy-Induced Febrile NeutropeniaHumansRetrospective StudiesFemaleMaleMiddle AgedAgedHospitalizationSensitivity and SpecificityAdultIntensive Care UnitsCohort StudiesLength of StayRisk Assessment

Stichwörter der Autor:innen

Febrile neutropeniaMASCCOncology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Centre Hospitalier Universitaire de Sherbrooke (CHUS), 3001 12E Avenue Nord, Sherbrooke, QC, J1H 5H3, Canada. charles-eric.rivest@usherbrooke.ca.
  • Université de Sherbrooke, Sherbrooke, Québec, Canada. charles-eric.rivest@usherbrooke.ca.
  • Centre Hospitalier Universitaire de Sherbrooke (CHUS), 3001 12E Avenue Nord, Sherbrooke, QC, J1H 5H3, Canada.
  • Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • CISSS Montérégie-Centre (Canada), Greenfield Park, Québec, Canada.
  • Centre de Recherche du Centre Hospitalier, Universitaire de Sherbrooke, Sherbrooke, QC, Canada.

Zitieren

APA

Rivest, C. E., Ben Abderrazik, F. E., Côté-Marcoux, M. A., Malick, M., Allard, C., Hanel, R., & Pavic, M. (2026). Correlation between MASCC score and the evolution of febrile neutropenia in patients with solid tumors: a retrospective study. Supportive Care in Cancer, 34(2). https://doi.org/10.1007/s00520-026-10375-w

Vancouver

Rivest CE, Ben Abderrazik FE, Côté-Marcoux MA, Malick M, Allard C, Hanel R, et al. Correlation between MASCC score and the evolution of febrile neutropenia in patients with solid tumors: a retrospective study. Supportive Care in Cancer. 2026;34(2). doi:10.1007/s00520-026-10375-w

BibTeX
@article{Rivest2026,
  author = {Rivest, Charles-Eric and Ben Abderrazik, Fatim Ezzahra and Côté-Marcoux, Marc-Antoine and Malick, Mandy and Allard, Catherine and Hanel, Robert and Pavic, Michel},
  title = {Correlation between MASCC score and the evolution of febrile neutropenia in patients with solid tumors: a retrospective study},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {2},
  doi = {10.1007/s00520-026-10375-w}
}
Kostenlos starten →